Physician profile
Patrick M Rood
NPI 1679681985
$14,144.51
in general payments reported to CMS, 2019-2025
55 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,453 · 2022: $4,604 · 2023: $3,760 · 2024: $2,043 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,885 · Consulting Fee: $150 · Education: $52.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,884.89 |
| Consulting Fee | $150.00 |
| Education | $52.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,478.16 | 2021-2023 | Tysabri, Vumerity, Spinraza |
| Mdd US Operations, LLC | $1,277.79 | 2021-2025 | Gocovri, Apokyn, Gocovri |
| Novartis Pharmaceuticals Corporation | $1,095.97 | 2021-2024 | |
| Abbvie INC. | $1,021.86 | 2021-2024 | |
| Horizon Therapeutics Plc | $823.70 | 2021-2023 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $800.67 | 2021-2024 | Austedo Xr, Austedo, Ajovy |
| Genentech USA, INC. | $684.06 | 2021-2024 | Ocrevus |
| Alexion Pharmaceuticals, INC. | $594.29 | 2021-2024 | Ultomiris, Soliris |
| Ucb, INC. | $512.27 | 2021-2024 | Rystiggo, Nayzilam, Briviact |
| Neurocrine Biosciences, INC. | $413.30 | 2021-2024 | Ingrezza |
| Acadia Pharmaceuticals INC | $356.33 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $353.96 | 2021-2024 | Rytary, Lyvispah |
| Tanabe Pharma America, INC. | $298.59 | 2021-2024 | |
| Pfizer INC. | $297.37 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $293.25 | 2021-2022 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $290.04 | 2021-2024 | Onpattro |
| Avanir Pharmaceuticals, INC. | $246.21 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $221.50 | 2023-2024 | Nuedexta |
| Biohaven Pharmaceutical Holding Company LTD. | $217.72 | 2022 | |
| Argenx US, INC. | $210.57 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $206.86 | 2021-2024 | Aimovig, Uplizna |
| Merz Pharmaceuticals, LLC | $171.50 | 2021-2022 | |
| Emd Serono, INC. | $164.09 | 2021-2023 | Mavenclad |
| Supernus Pharmaceuticals, INC. | $164.08 | 2021-2025 | Qelbree |
| Banner Life Sciences, LLC | $153.11 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $152.91 | 2021 | |
| Csl Behring | $145.36 | 2022-2024 | Hizentra, Kcentra |
| Celgene Corporation | $132.24 | 2022-2024 | Zeposia |
| Genzyme Corporation | $131.77 | 2021-2023 | |
| Tg Therapeutics, INC. | $119.87 | 2023-2024 | |
| Lundbeck LLC | $112.84 | 2021-2024 | Vyepti |
| Mallinckrodt Hospital Products INC. | $100.99 | 2021-2023 | Acthar |
| Grt US Holding, INC. | $92.41 | 2021-2022 | |
| Lilly USA, LLC | $90.60 | 2021-2024 | Emgality, Reyvow |
| Catalyst Pharmaceuticals, INC. | $65.93 | 2022-2023 | Firdapse |
| Biohaven Pharmaceuticals, INC. | $64.10 | 2021 | |
| Axsome Therapeutics, INC. | $63.31 | 2023-2024 | Sunosi |
| Scilex Pharmaceuticals INC. | $63.16 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $58.46 | 2022-2023 | Quviviq |
| Sk Life Science, INC. | $54.28 | 2021-2022 | |
| Kyowa Kirin, INC. | $42.22 | 2023-2024 | Nourianz |
| Acorda Therapeutics, INC | $39.14 | 2022-2023 | Inbrija, Ampyra |
| Octapharma USA, INC. | $31.81 | 2023-2024 | Panzyga |
| Eisai INC. | $30.87 | 2021 | |
| Harmony Biosciences LLC | $28.87 | 2023 | Wakix |
| Xeris Pharmaceuticals, INC. | $23.82 | 2022 | |
| Kedrion Biopharma, INC. | $21.94 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Gammaked |
| Grifols USA, LLC | $20.75 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.78 | 2023 | Gammagard |
| Jazz Pharmaceuticals INC. | $19.49 | 2022 | |
| Abbott Laboratories | $15.09 | 2022 | |
| Ani Pharmaceuticals, INC. | $14.39 | 2022 | |
| Akcea Therapeutics, INC. | $14.25 | 2021 | |
| Allergan, INC. | $13.86 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $12.75 | 2023 | Relyvrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Rood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.